The global antidiabetics market size was valued at USD 82.85 billion in 2023 and is anticipated to reach around USD 263.12 billion by 2033, growing at a CAGR of 12.25% from 2024 to 2033.
The expansion of the market is attributed to factors such as the global rise in diabetes prevalence due to unhealthy diets, sedentary lifestyles, and a surge in the geriatric population. Advances in medical research and technology have led to the entry of innovative antidiabetic drugs in the market with improved efficacy and safety. Furthermore, increased awareness of diabetes management and early intervention has boosted patient adherence to therapies. These drivers, along with improved healthcare access and initiatives targeting diabetes-related complications, are propelling the ongoing growth of the market.
The escalating global prevalence of diabetes, encompassing both type I and type II, is projected to play a pivotal role in driving the demand for insulin and oral hypoglycemic drugs. The IDF Diabetes Atlas, in its 10th edition, highlights an ongoing surge in prevalence worldwide, establishing it as a substantial global health challenge. The report reveals that a staggering 537 million adults (aged 20-79) currently deal with diabetes, accounting for 1 in 10 individuals. Projections indicate a further escalation to 643 million by 2030 and 783 million by 2045, underscoring the urgency for effective management and treatment strategies.
A multitude of significant market drivers contribute to this growth trajectory, encompassing the rising incidence of lifestyle-related conditions like obesity, an expanding global elderly populace, research and development endeavors focused on novel product innovation and a robust pipeline portfolio. An examination of trends by BMI categories, as highlighted in the Circulation Research study in 2023, emphasizes that diabetes exhibited an increase solely among the obese population (18.0% to 20.1%), indicating that much of the surge in diabetic prevalence can be attributed to the rising rates of obesity.
Recent advancements have propelled market growth, for instance by Dr. Reddy's Laboratories' introduction of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets, a generic variant of antidiabetic medication, into the U.S. market on August 10, 2023. Moreover, players are aiming at portfolio expansion and diversification. In March 2023, Sanofi announced the acquisition of Provention Bio for its antidiabetic product Tzield, allowing it to diversify its diabetes portfolio.
| Report Attribute | Details |
| Market Size in 2024 | USD 93.00 Billion |
| Market Size by 2033 | USD 263.12 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 12.25% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Drug class, diabetics type, route of administration, distribution channel, region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | AstraZeneca plc; Bayer AG; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Boehringer Ingelheim; Bristol-Myers Squibb; Pfizer, Inc.; Johnson & Johnson Services Inc.; Merck & Co. Inc ; Novartis AG |
The U.S. antidiabetics market size was valued at USD 30.92 billion in 2023 and is projected to surpass around USD 98.37 billion by 2033, registering a CAGR of 12.27% over the forecast period of 2024 to 2033.
North America market accounted for the largest share of 42.11% in 2023. The region has a notably high prevalence of diabetes, primarily type 2 diabetes, which has increased due to lifestyle changes and an aging population. Additionally, the region’s well-developed healthcare infrastructure and high healthcare expenditure allow for extensive diabetes management and treatment options, contributing to the market's dominance. North America is home to several prominent pharmaceutical companies and research institutions specializing in diabetic care and innovation. These organizations continuously develop and introduce new antidiabetic drugs and technologies, fostering growth in the market.
U.S. Antidiabetics Market Trends
The market in the U.S. is expected to grow over the forecast period due to several factors, including advancements in clinical research, increasing number of FDA-approved drugs, and a strong R&D pipeline. According to an article published by the Frontiers in June 2022, nearly 100 . antihyperglycemic agents are currently being evaluated for type 2 diabetes and 60 drugs have been approved.
Europe Antidiabetics Market Trends
Europe market is experiencing significant growth majorly due to high prevalence and the increasing financial burden of diabetes. It is one of the leading cause of death in the region, however, the prevalence & mortality rate vary significantly between European countries.
UK antidiabetics market is driven by increasing prescription rate as compared to the historic years and rising demand for innovative antidiabetics as the government focuses on improving public health.
The antidiabetics market in France is expected to grow over the forecast period due to rising awareness about the management of the disease. DPP-4 inhibitors and GLP-1 receptor agonists were the most prescribed drug class in 2021.
Germany antidiabetics market is expected to grow at a lucrative rate over the forecast period. This can be attributed to the ongoing advancements by public and private organizations, rising geriatric population, and focus on R&D by various companies headquartered in Germany
Asia Pacific Antidiabetics Market Trends
Asia Pacific market is estimated to grow at the fastest rate during the forecast period. Asia Pacific has witnessed a significant surge in diabetic cases, particularly type 2 diabetes, due to changing lifestyles, urbanization, and dietary habits. The region is home to a large and growing population, making it a substantial market for diabetes management and treatment. Moreover, the trend is the expansion of telemedicine and digital health solutions in the region. COVID-19 accelerated the adoption of remote healthcare services, including teleconsultations and digital platforms for diabetes management. The adoption of digital health solutions, positioning it as a key growth area for diabetes’s related products and services in the coming years.
The antidiabetics market in China is expected to grow over the forecast period owing to the high prevalence of the condition. According to a leading endocrinologist in China, nearly 114 million people are living with diabetes in China which is 40%-60% of the total population of diabetes globally.
Japan antidiabetics market is expected to grow over the forecast period due to the presence of well-established healthcare system. According to the IDF, over 7.4 million Japanese individuals were living with diabetes in 2020. Westernized lifestyle, unhealthy diet, lack of exercise, and aging population are major risk factors boosting the prevalence of diabetes in the country.
Latin America Antidiabetics Market Trends
Latin America market was identified as a lucrative region in this industry. A large section of society in South America is aging rapidly, which has led to an increase in healthcare expenditure and is driving market growth in the region.
The antidiabetics market in Brazil is expected to grow over the forecast period. Over the years, Brazil has enacted several changes to introduce new financing methods, establish new service organization types, enhance the distribution of doctors, and execute a range of quality improvement programs and policy frameworks. This also demonstrates potential areas for further and ongoing advancements in diabetes therapy.
MEA Antidiabetics Market Trends
MEA market is primarily driven by increasing focus of government to curb the alarming prevalence of diabetes in MEA countries and shift in dietary and lifestyle patterns leading to obesity and other metabolic disorders.
The antidiabetics market in Saudi Arabia is experiencing significant growth, driven by substantial government investment in pharmaceuticals. Organizations such as the Saudi Diabetes & Endocrine Association (SDEA) are creating general awareness among the population. Additionally, growing technological advancements in R&D of drug delivery is expected to increase the prescription rate for a product, driving the market.
GLP-1 receptor agonists segment dominated the market in 2023 with a share of 35.96% and is expected to grow at the fastest CAGR by 2033. This growth can be attributed to its high efficacy for managing type 2 diabetes and its potential advantages to patients, such as being effective in regulating blood sugar levels and promoting insulin production, making them a preferred therapeutic choice for diabetes management. The high growth rate of this segment is underpinned by its ability to address critical medical needs and deliver tangible benefits to patients.
The advancements in treatment modalities, increasing awareness about diabetes management, and the introduction of patient-friendly options like oral GLP-1 receptor agonists have all contributed to the growing dominance of the segment. The introduction of innovative treatment options, the ongoing efforts to enhance patient experiences, and the continuous exploration of GLP-1 receptor agonists' potential in diabetes management contribute to the anticipated robust growth. For instance, in June 2023, Pfizer announced that it is actively progressing its clinical development program for GLP-1 receptor agonists (GLP-1-RAs), focusing on danuglipron, the first full agonist oral candidate. This effort is aimed at addressing obesity and type 2 diabetes mellitus. Pfizer's commitment to advancing danuglipron towards late-stage development demonstrates its dedication to providing innovative solutions for managing these health challenges.
Diabetes type 2 segment dominated the market in 2023 with a market share of 79.91% and is expected to grow at the fastest CAGR from 2024 to 2033. This growth be attributed to the increasing prevalence of this chronic condition globally. According to the IMHE report June 2023, the global diabetes cases to soar from 529 million to 1.3 billion by 2050 As more individuals are diagnosed with type 2 diabetes, the demand for effective management and treatment options grows, leading to the segment's substantial market share. The increasing awareness about diabetes prevention, management, and the development of innovative therapies and technologies are projected to drive this growth.
The rising need to address the healthcare burden posed by type 2 diabetics and its associated complications is motivating both research and industry to invest in solutions that offer better patient outcomes and contribute to this market segment's ongoing dominance. For instance, in July 2023, Dexcom, a prominent global leader in real-time continuous glucose monitoring (rtCGM) solutions for individuals with diabetes, received Health Canada's approval for its advanced Dexcom G7 Continuous Glucose Monitoring System. This innovative system is now authorized for use by individuals of all diabetic types aged two years and older, offering enhanced diabetic management capabilities. These advancements support easy monitoring and treatment of the condition, thereby boosting the demand for treatments.
Intravenous segment dominated the market in 2023 with a share of 42.81%. The intravenous administration of antidiabetic medications offers immediate and precise control over blood glucose levels, proving particularly invaluable during critical scenarios like diabetic ketoacidosis or hyperglycemic emergencies. This immediate impact on glucose regulation positions intravenous treatments as pivotal for addressing acute diabetic complications. Moreover, advancements and drug approvals in intravenous drug formulations and delivery technologies have improved the efficacy and safety of this approach, sustaining its market dominance. For instance, in May 2022, Mounjaro (tirzepatide) injection received approval by the U.S. Food and Drug Administration. The injection is an advanced treatment enhancing blood sugar management for adults with type 2 diabetes. Mounjaro demonstrated remarkable efficacy, outperforming other diabetes treatments in clinical trials.
Subcutaneous segment is estimated to grow at the fastest rate during the forecast period. The subcutaneous method of giving diabetes medication is easier for patients. They can give themselves shots or use less invasive devices, so they don't have to see the doctor or stay in the hospital as often. Subcutaneous diabetic drugs also work quickly, helping control blood sugar better, which is really important for people with diabetes. Some prominent players are working with tech giants to make smart insulin pens that connect to phone apps. This makes it easier to track blood sugar and get advice on how much insulin to use. This shows how diabetes care is changing and getting better for patients. For instance, in August 2023, Insulet released the Omnipod 5 Automated Insulin Delivery System in Germany, which is a big step forward in how to treat diabetes. The increasing adoption of these novel delivery segments is projected to drive the segment growth.
Hospital pharmacies segment held the largest market share of 50.11% in 2023. Hospitals are often the primary care providers for patients with diabetes, especially those with severe or complicated cases. This central role allows hospital pharmacies to have a strong influence in shaping treatment protocols and prescribing decisions. Moreover, they have access to a wide range of antidiabetic medications and resources, ensuring that patients receive the most suitable and effective treatments this comprehensive approach fosters patient trust and loyalty, further solidifying the hospital pharmacies' dominant position in the market.
In a major development, a major pharmaceutical company has entered into a strategic partnership with a prominent hospital network. As part of this collaboration, the pharmaceutical company has exclusively provided its latest antidiabetic medication to the hospital network, reinforcing the hospitals' role in prescribing and administering the drug. For example, in August 2023, Shields Health Solutions, a leading specialty pharmacy accelerator, joined forces with Erlanger, a respected multi-hospital health system based in Tennessee. Together, they launched an innovative specialty pharmacy program within the hospital pharmacy. This initiative aims to enhance access to specialized pharmacy services for patients dealing with complex, chronic conditions, focusing on cost reduction, treatment expansion, improved medication management, and overall health enhancement.
Online pharmacies segment is estimated to grow at the fastest CAGR from 2024 to 2033. The growth of the segment is due to the ease of ordering medications from the comfort of their homes and having them delivered to their doorstep, diabetic individuals no longer face the hassle of visiting physical pharmacies or waiting in queues. For instance, in November 2020, Amazon.com, Inc. introduced two pharmacy services for prescription medications. Amazon Pharmacy enables customers to complete pharmacy transactions seamlessly on their desktop or mobile devices via the Amazon App. This accessibility significantly enhances medication adherence, a critical factor in disease management. Moreover, the vast availability of antidiabetic drugs from different brands and generic alternatives online empowers patients with choices, fostering competition and potentially lowering overall treatment costs.
The following are the leading companies in the antidiabetics market. These companies collectively hold the largest market share and dictate industry trends.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Antidiabetics market.
By Drug Class
By Diabetes Type
By Route of administration
By Distribution Channel
By Region
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers